Literature DB >> 18230361

Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates.

Brent L Nannenga1, Andleeb Zameer, Michael R Sierks.   

Abstract

Huntington's and Parkinson's diseases are both neurodegenerative disorders caused at least in part by misfolding and aggregation of huntingtin (htt) and alpha-synuclein, respectively. Here we use a single chain antibody fragment (scFv) isolated against oligomeric alpha-synuclein to probe similarities and differences between the aggregation and toxic mechanisms of htt and alpha-synuclein. When incubated with htt, the scFv both blocks formation of and promotes dissociation of fibrillar aggregates, but stabilizes formation of cytotoxic oligomeric aggregates. Previous studies with monomeric alpha-synuclein showed the scFv prevented fibrillar aggregation, but blocked toxicity of oligomeric aggregates. These divergent effects suggest the toxic mechanisms of oligomeric aggregates differ among amyloidogenic protein species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230361     DOI: 10.1016/j.febslet.2008.01.014

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.

Authors:  Erik Kvam; Michael R Sierks; Charles B Shoemaker; Anne Messer
Journal:  Protein Eng Des Sel       Date:  2010-04-08       Impact factor: 1.650

2.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

3.  Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.

Authors:  Vijay Gupta; Safa Salim; Issam Hmila; Nishant N Vaikath; Indulekha P Sudhakaran; Simona S Ghanem; Nour K Majbour; Sara A Abdulla; Mohamed M Emara; Houari B Abdesselem; Tamas Lukacsovich; Daniel Erskine; Omar M A El-Agnaf
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

Review 4.  Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers.

Authors:  André L B Bitencourt; Raquel M Campos; Erika N Cline; William L Klein; Adriano Sebollela
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

Review 5.  Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.

Authors:  Liang Huang; Xiaomin Su; Howard J Federoff
Journal:  Int J Mol Sci       Date:  2013-09-17       Impact factor: 5.923

Review 6.  Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy.

Authors:  Kristen Marciniuk; Ryan Taschuk; Scott Napper
Journal:  Clin Dev Immunol       Date:  2013-10-20

Review 7.  Recombinant Antibody Fragments for Neurodegenerative Diseases.

Authors:  Karen Manoutcharian; Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.